Epithalon: Research Overview

Epithalon (also spelled Epitalon; also called AEDG) is a synthetic tetrapeptide with the amino acid sequence Ala-Glu-Asp-Gly. It was developed by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, Russia, as a synthetic analogue of Epithalamin — a bovine pineal gland polypeptide extract. Research on Epithalon has focused principally on telomerase activation and anti-aging effects in cell culture and animal models. Readers should note that the substantial majority of published Epithalon research originates from a single research group, which limits independent replication of findings.

What Is Epithalon?

Epithalon has a molecular weight of approximately 390 Da and a very short plasma half-life (measured in minutes). It is classified as a longevity-research compound based on its ability to activate telomerase — the enzyme that extends telomere length — in cell culture models. Telomere shortening is associated with cellular senescence and aging, and telomerase reactivation is theoretically a mechanism for extending cellular lifespan. Whether these in vitro and animal observations translate to meaningful effects in healthy adult humans has not been demonstrated.

Mechanism of Action

In cell culture studies, Epithalon has been shown to induce telomerase activity (specifically hTERT, the catalytic subunit) and promote telomere elongation in human fetal fibroblasts and other somatic cell lines that are ordinarily telomerase-negative. Khavinson et al. (2003, PMID 12937682) reported that telomerase-negative fibroblast cultures treated with Epithalon continued dividing beyond the normal Hayflick limit, with treated cultures maintaining proliferative capacity through the 44th passage versus loss of mitotic activity after the 34th passage in untreated controls. The mechanism by which a four-amino-acid peptide activates hTERT is not fully characterized.

What the Research Shows

The core published findings on Epithalon consist of: (1) in vitro telomerase induction and telomere elongation in human somatic cells (Khavinson et al., 2003; PMID 12937682); (2) lifespan extension in fruit fly (Drosophila) and rodent models in studies conducted by the Khavinson group; and (3) a small human study reporting increased telomere length in blood cells of elderly subjects (ages 60–80) following Epithalamin or Epithalon administration, also from the same Russian group.

An independent 2025 study (PMC 12411320) confirmed dose-dependent telomere extension in normal cell lines through hTERT upregulation, providing the first substantive independent replication of telomerase activation findings. However, no randomized controlled human trials evaluating clinical outcomes with Epithalon have been published by independent research groups. The evidence base is real but narrow, and readers should weight it accordingly.

Reported Dose Ranges

DISCLAIMER: The following information is provided for research reference only and is not medical advice or a recommendation to use this compound. Published dose-range data in humans is limited and almost exclusively originates from a single research group. The ranges below are drawn from that literature and should not be interpreted as established clinical dosing.

The human studies published by the Khavinson group used intravenous and intramuscular administration in elderly subjects, with typical doses in the range of 1–10 mg per session administered in courses of multiple injections over days to weeks. However, these protocols have not been reproduced in independently conducted clinical trials. Research peptide vendors supply Epithalon in lyophilized form; literature reporting subcutaneous use at 5–10 mg exists in non-peer-reviewed sources. No published phase 1 pharmacokinetic study defines a dose-response relationship in humans.

Storage

Lyophilized Epithalon should be stored at −20 °C in a desiccated environment. Reconstituted solutions should be kept at 2–8 °C and used within 7 days given the compound’s short half-life.